Literature DB >> 28933281

Influenza Virus: Small Molecule Therapeutics and Mechanisms of Antiviral Resistance.

Julianna Han1, Jasmine Perez1, Adam Schafer2, Han Cheng2, Norton Peet3, Lijun Rong2, Balaji Manicassamy1.   

Abstract

BACKGROUND: Influenza viruses cause severe upper respiratory illness in children and the elderly during seasonal epidemics. Influenza viruses from zoonotic reservoirs can also cause pandemics with significant loss of life in all age groups. Although vaccination is one of the most effective methods to protect against seasonal epidemics, seasonal vaccines vary in efficacy, can be ineffective in the elderly population, and do not provide protection against novel strains. Small molecule therapeutics are a critical part of our antiviral strategies to control influenza virus epidemics and pandemics as well as to ameliorate disease in elderly and immunocompromised individuals.
OBJECTIVE: This review aims to summarize the existing antiviral strategies for combating influenza viruses, the mechanisms of antiviral resistance for available drugs, and novel therapeutics currently in development.
METHODS: We systematically evaluated and synthesized the published scientific literature for mechanistic detail into therapeutic strategies against influenza viruses.
RESULTS: Current IAV strains have developed resistance to neuraminidase inhibitors and nearly complete resistance to M2 ion channel inhibitors, exacerbated by sub-therapeutic dosing used for treatment and chemoprophylaxis. New tactics include novel therapeutics targeting host components and combination therapy, which show potential for fighting influenza virus disease while minimizing viral resistance.
CONCLUSION: Antiviral drugs are crucial for controlling influenza virus disease burden, but their efficacy is limited by human misuse and the capacity of influenza viruses to circumvent antiviral barriers. To relieve the public health hardship of influenza virus, emerging therapies must be selected for their capacity to impede not only influenza virus disease, but also the development of antiviral resistance. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Influenza virus; anti-influenza drugs; antiviral drugs; antiviral resistance; small molecule therapeutics.

Mesh:

Substances:

Year:  2018        PMID: 28933281      PMCID: PMC8735713          DOI: 10.2174/0929867324666170920165926

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  104 in total

1.  Oseltamivir resistance--disabling our influenza defenses.

Authors:  Anne Moscona
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

Review 2.  Neuraminidase inhibitors: who, when, where?

Authors:  J S Nguyen-Van-Tam; S Venkatesan; S G Muthuri; P R Myles
Journal:  Clin Microbiol Infect       Date:  2014-11-27       Impact factor: 8.067

3.  Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir.

Authors:  Mariana Baz; Yacine Abed; Guy Boivin
Journal:  Antiviral Res       Date:  2006-11-20       Impact factor: 5.970

4.  Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level.

Authors:  Jean François Rossignol; Simone La Frazia; Lucia Chiappa; Alessandra Ciucci; M Gabriella Santoro
Journal:  J Biol Chem       Date:  2009-07-28       Impact factor: 5.157

5.  Zanamivir-resistant influenza viruses with a novel neuraminidase mutation.

Authors:  Aeron C Hurt; Jessica K Holien; Michael Parker; Anne Kelso; Ian G Barr
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

6.  Pathogenesis of Influenza D Virus in Cattle.

Authors:  Lucas Ferguson; Alicia K Olivier; Suzanne Genova; William B Epperson; David R Smith; Liesel Schneider; Kathleen Barton; Katlin McCuan; Richard J Webby; Xiu-Feng Wan
Journal:  J Virol       Date:  2016-05-27       Impact factor: 5.103

7.  Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol.

Authors:  Irina A Leneva; Rupert J Russell; Yury S Boriskin; Alan J Hay
Journal:  Antiviral Res       Date:  2008-11-24       Impact factor: 5.970

8.  Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses.

Authors:  Mariana Baz; Yacine Abed; Philippe Simon; Marie-Eve Hamelin; Guy Boivin
Journal:  J Infect Dis       Date:  2010-03       Impact factor: 5.226

9.  Isolation of a novel swine influenza virus from Oklahoma in 2011 which is distantly related to human influenza C viruses.

Authors:  Ben M Hause; Mariette Ducatez; Emily A Collin; Zhiguang Ran; Runxia Liu; Zizhang Sheng; Anibal Armien; Bryan Kaplan; Suvobrata Chakravarty; Adam D Hoppe; Richard J Webby; Randy R Simonson; Feng Li
Journal:  PLoS Pathog       Date:  2013-02-07       Impact factor: 6.823

Review 10.  Antiviral combinations for severe influenza.

Authors:  Jake Dunning; J Kenneth Baillie; Bin Cao; Frederick G Hayden
Journal:  Lancet Infect Dis       Date:  2014-09-08       Impact factor: 25.071

View more
  20 in total

1.  Identification of entry inhibitors with 4-aminopiperidine scaffold targeting group 1 influenza A virus.

Authors:  Amira F A Hussein; Han Cheng; Smanla Tundup; Aleksandar Antanasijevic; Elizabeth Varhegyi; Jasmine Perez; Eiman M AbdulRahman; Mervat G Elenany; Soheir Helal; Michael Caffrey; Norton Peet; Balaji Manicassamy; Lijun Rong
Journal:  Antiviral Res       Date:  2020-03-25       Impact factor: 5.970

2.  Identification of a novel inhibitor targeting influenza A virus group 2 hemagglutinins.

Authors:  Ruikun Du; Han Cheng; Qinghua Cui; Norton P Peet; Irina N Gaisina; Lijun Rong
Journal:  Antiviral Res       Date:  2021-01-08       Impact factor: 5.970

3.  Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza.

Authors:  Claire Scott; Jayakanth Kankanala; Toshana L Foster; Daniel H Goldhill; Peng Bao; Katie Simmons; Marieke Pingen; Matthew Bentham; Elizabeth Atkins; Eleni Loundras; Ruth Elderfield; Jolyon K Claridge; Joseph Thompson; Peter R Stilwell; Ranjitha Tathineni; Clive S McKimmie; Paul Targett-Adams; Jason R Schnell; Graham P Cook; Stephen Evans; Wendy S Barclay; Richard Foster; Stephen Griffin
Journal:  PLoS Pathog       Date:  2020-08-11       Impact factor: 6.823

4.  OP7, a novel influenza A virus defective interfering particle: production, purification, and animal experiments demonstrating antiviral potential.

Authors:  Marc D Hein; Heike Kollmus; Pavel Marichal-Gallardo; Sebastian Püttker; Dirk Benndorf; Yvonne Genzel; Klaus Schughart; Sascha Y Kupke; Udo Reichl
Journal:  Appl Microbiol Biotechnol       Date:  2020-12-04       Impact factor: 4.813

5.  Cell culture-based production and in vivo characterization of purely clonal defective interfering influenza virus particles.

Authors:  Marc D Hein; Prerna Arora; Pavel Marichal-Gallardo; Michael Winkler; Yvonne Genzel; Stefan Pöhlmann; Klaus Schughart; Sascha Y Kupke; Udo Reichl
Journal:  BMC Biol       Date:  2021-05-03       Impact factor: 7.431

Review 6.  Small Molecule Inhibitors of Influenza Virus Entry.

Authors:  Zhaoyu Chen; Qinghua Cui; Michael Caffrey; Lijun Rong; Ruikun Du
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-18

Review 7.  Antiviral potential of natural products from marine microbes.

Authors:  Mengqi Yi; Sixiao Lin; Bin Zhang; Haixiao Jin; Lijian Ding
Journal:  Eur J Med Chem       Date:  2020-08-31       Impact factor: 6.514

8.  A Parallel Phenotypic Versus Target-Based Screening Strategy for RNA-Dependent RNA Polymerase Inhibitors of the Influenza A Virus.

Authors:  Xiujuan Zhao; Yanyan Wang; Qinghua Cui; Ping Li; Lin Wang; Zinuo Chen; Lijun Rong; Ruikun Du
Journal:  Viruses       Date:  2019-09-05       Impact factor: 5.048

Review 9.  Next-generation direct-acting influenza therapeutics.

Authors:  Mart Toots; Richard K Plemper
Journal:  Transl Res       Date:  2020-02-04       Impact factor: 7.012

10.  Pharmacological inhibition of poly (ADP-ribose) polymerase by olaparib ameliorates influenza-virus-induced pneumonia in mice.

Authors:  Wei Liu; Xiaojuan Ren; Qian Wang; Yan Zhang; Junfeng Du
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-08-31       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.